Effects of Peppermint Oil in Cardiometabolic Outcomes

Sponsor
University of Central Lancashire (Other)
Overall Status
Recruiting
CT.gov ID
NCT05071833
Collaborator
(none)
24
1
2
26.9
0.9

Study Details

Study Description

Brief Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. Previous non-randomized interventions have shown that oral peppermint may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in healthy individuals.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Peppermint oil.
  • Other: Placebo
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Effects of Oral Peppermint Supplementation on Cardiometabolic Parameters
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Identical in taste and colour to the supplement juice, but with no peppermint content.

Other: Placebo
Placebo

Experimental: Peppermint oil

50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.

Dietary Supplement: Peppermint oil.
Peppermint oil.

Outcome Measures

Primary Outcome Measures

  1. Blood pressure [Baseline]

    Systolic and diastolic blood pressure - measured using a digital blood pressure monitor

  2. Blood pressure [20 days]

    Systolic and diastolic blood pressure - measured using a digital blood pressure monitor

  3. Percent bodyfat [Baseline]

    Participants percentage composition of fat - measured using bio-electrical impedance

  4. Percent bodyfat [20 days]

    Participants percentage composition of fat - measured using bio-electrical impedance

  5. Waist to hip ratio [Baseline]

    Ratio of waist to hip circumference - measured using anthropocentric tape

  6. Waist to hip ratio [20 days]

    Ratio of waist to hip circumference - measured using anthropocentric tape

  7. Resting metabolic rate [Baseline]

    Estimated daily calorie usage (Kcal) at rest - obtained using a metabolic cart through indirect calorimetry.

  8. Resting metabolic rate [20 days]

    Estimated daily calorie usage (Kcal) at rest - obtained using a metabolic cart through indirect calorimetry.

  9. Resting utilization of carbohydrates [Baseline]

    Percent contribution of carbohydrate to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry.

  10. Resting utilization of carbohydrates [20 days]

    Percent contribution of carbohydrate to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry.

  11. Resting utilization of fats [Baseline]

    Percent contribution of fats to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry.

  12. Resting utilization of fats [20 days]

    Percent contribution of fats to daily calories - at rest - obtained using a metabolic cart through indirect calorimetry.

  13. Low-moderate intensity activity calories expended [Baseline]

    Estimated calorie usage (Kcal) during low-moderate intensity walking exercise - obtained using a metabolic cart through indirect calorimetry.

  14. Low-moderate intensity activity calories expended [20 days]

    Estimated calorie usage (Kcal) during low-moderate intensity walking exercise - obtained using a metabolic cart through indirect calorimetry.

  15. Low-moderate intensity activity utilization of fats [Baseline]

    Percent contribution of fats to calorie expenditure - during low-moderate intensity walking exercise - obtained using a metabolic cart through indirect calorimetry.

  16. Low-moderate intensity activity utilization of fats [20 days]

    Percent contribution of fats to calorie expenditure - during low-moderate intensity walking exercise - obtained using a metabolic cart through indirect calorimetry.

  17. Low-moderate intensity activity utilization of carbohydrates [Baseline]

    Percent contribution of carbohydrates to calorie expenditure - during low intensity walking exercise - obtained using a metabolic cart through indirect calorimetry.

  18. Low-moderate intensity activity utilization of carbohydrates [20 days]

    Percent contribution of carbohydrates to calorie expenditure - during low intensity walking exercise - obtained using a metabolic cart through indirect calorimetry.

  19. Blood glucose [Baseline]

    Capillary blood glucose - mmol/L

  20. Blood glucose [20 days]

    Capillary blood glucose - mmol/L

  21. Blood triglycerides [Baseline]

    Capillary blood triglycerides - mmol/L

  22. Blood triglycerides [20 days]

    Capillary blood triglycerides - mmol/L

  23. Blood cholesterol (Total, HDL & LDL) [Baseline]

    Capillary blood cholesterol - mmol/L

  24. Blood cholesterol (Total, HDL & LDL) [20 days]

    Capillary blood cholesterol - mmol/L

  25. Blood haemoglobin [Baseline]

    Capillary blood haemoglobin - g/L

  26. Blood haemoglobin [20 days]

    Capillary blood haemoglobin - g/L

  27. Coop-Wonka chart [Baseline]

    Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

  28. Coop-Wonka chart [20 days]

    Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

  29. Beck Depression Inventory [Baseline]

    Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

  30. Beck Depression Inventory [20 days]

    Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

  31. State Trait Anxiety Inventory [Baseline]

    Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

  32. State Trait Anxiety Inventory [20 days]

    Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

  33. Insomnia Severity Index [Baseline]

    Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

  34. Insomnia Severity Index [20 days]

    Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

  35. Pittsburgh Sleep Quality Index [Baseline]

    Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

  36. Pittsburgh Sleep Quality Index [20 days]

    Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

  37. Epworth Sleepiness Scale [Baseline]

    Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

  38. Epworth Sleepiness Scale [20 days]

    Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy

  • Between 18 & 65 years

  • Non-smoker

  • BMI < 30

  • Able to give informed consent

Exclusion Criteria:
  • Pregnancy

  • Diabetes or any other metabolic/ uncontrolled hypertensive conditions

  • Food allergies to peppermint

  • Habitual consumption of peppermint

  • Not regularly taking medication or antioxidant supplements

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jonathan Sinclair Preston Lancashire United Kingdom PR4 0PE

Sponsors and Collaborators

  • University of Central Lancashire

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jonathan Sinclair, Professor, University of Central Lancashire
ClinicalTrials.gov Identifier:
NCT05071833
Other Study ID Numbers:
  • Peppermint oil cardiometabolic
First Posted:
Oct 8, 2021
Last Update Posted:
Jul 12, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 12, 2022